Cholesterol management is not simply about blocking a single enzyme (as statins do). Optimal lipid balance involves hepatic cholesterol synthesis and clearance, lipoprotein structure and particle size, triglyceride metabolism, inflammation, insulin sensitivity, and body composition, all of which are influenced by peptide signaling.
Growth hormone optimization via secretagogue peptides (CJC-1295, Ipamorelin) has well-documented effects on lipid profiles: GH lowers LDL, raises HDL, and reduces visceral fat, all favorable cardiovascular outcomes. AOD-9604, a fragment of HGH, specifically targets fat metabolism and has shown lipid-improving effects.
BPC-157 has demonstrated hepatoprotective effects in research, protecting the liver from damage and supporting optimal hepatic function, which is central to cholesterol processing. Optimizing growth hormone consistently improves the LDL/HDL ratio in clinical studies.
At Body Symmetry MD, we assess your complete cardiovascular risk picture, including LDL particle number, ApoB, hs-CRP, insulin resistance markers, and body composition, before designing a peptide protocol to address your specific lipid issues at the root level.
